Utilize este identificador para referenciar este registo: https://hdl.handle.net/10216/126468
Registo completo
Campo DCValorIdioma
dc.creatorSalehi, B-
dc.creatorMishra, A-
dc.creatorNigam, M-
dc.creatorSener, B-
dc.creatorKilic, M-
dc.creatorSharifi-Rad, M-
dc.creatorFokou, P-
dc.creatorMartins, N-
dc.creatorSharifi-Rad, J-
dc.date.accessioned2020-03-02T10:33:56Z-
dc.date.available2020-03-02T10:33:56Z-
dc.date.issued2018-
dc.identifier.issn2227-9059-
dc.identifier.urihttps://hdl.handle.net/10216/126468-
dc.description.abstractResveratrol (3,5,4'-trihydroxy-trans-stilbene) belongs to polyphenols' stilbenoids group, possessing two phenol rings linked to each other by an ethylene bridge. This natural polyphenol has been detected inmore than 70 plant species, especially in grapes' skin and seeds, and was found in discrete amounts in red wines and various human foods. It is a phytoalexin that acts against pathogens, including bacteria and fungi. As a natural food ingredient, numerous studies have demonstrated that resveratrol possesses a very high antioxidant potential. Resveratrol also exhibit antitumor activity, and is considered a potential candidate for prevention and treatment of several types of cancer. Indeed, resveratrol anticancer properties have been confirmed bymany in vitro and in vivo studies, which shows that resveratrol is able to inhibit all carcinogenesis stages (e.g., initiation, promotion and progression). Evenmore, other bioactive effects, namely as anti-inflammatory, anticarcinogenic, cardioprotective, vasorelaxant, phytoestrogenic and neuroprotective have also been reported. Nonetheless, resveratrol application is still being a major challenge for pharmaceutical industry, due to its poor solubility and bioavailability, as well as adverse effects. In this sense, this review summarized current data on resveratrol pharmacological effects.-
dc.description.sponsorshipN. Martins would like to thank the Portuguese Foundation for Science and Technology (FCT–Portugal) for the Strategic project ref. UID/BIM/04293/2013 and “NORTE2020 - Programa Operacional Regional do Norte” (NORTE-01-0145-FEDER-000012).-
dc.language.isoeng-
dc.publisherMDPI-
dc.relationinfo:eu-repo/grantAgreement/FCT/5876/147342/PT-
dc.relation.ispartofBiomedicines, vol.6(3):91-
dc.rightsopenAccess-
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/-
dc.subjectanticancer-
dc.subjectantimicrobial-
dc.subjectantioxidant-
dc.subjectpharmacological activity-
dc.subjectphysiological effects-
dc.subjectresveratrol-
dc.titleResveratrol: A double-edged sword in health benefits-
dc.typeArtigo em Revista Científica Internacional-
dc.contributor.uportoInstituto de Investigação e Inovação em Saúde-
dc.identifier.doi10.3390/biomedicines6030091-
dc.relation.publisherversionhttps://www.mdpi.com/2227-9059/6/3/91-
Aparece nas coleções:I3S - Artigo em Revista Científica Internacional

Ficheiros deste registo:
Ficheiro Descrição TamanhoFormato 
10.3390-biomedicines6030091.pdf875.34 kBAdobe PDFThumbnail
Ver/Abrir


Este registo está protegido por Licença Creative Commons Creative Commons